Mim8 Novo Nordisk - Search News

News

Novo Nordisk, Wegovy and Hims

Zacks Investment Research on M… · 5d

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic headwinds. A key catalyst was last week’s announcement from rival Eli Lilly LLY, which reported first phase III success for its oral GLP-1 candidate,

The Hill on MSN · 30m

Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would

Seeking Alpha on MSN · 7h

Hims & Hers surges on partnership with Novo Nordisk for Wegovy

Hims & Hers Health (HIMS) stock surges following a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker's weight loss drug, Wegovy. Read more here.

Zacks Investment Research on MSN5h

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

Fierce Pharma4d

US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutide

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results